Hodgkin lymphoma. ASCO, EHA and ASH 2020 news
The review shows the most interesting and promising studies presented at major international conferences of the American Society of Clinical Oncology, the European Hematology Association, and the American Society of Hematology in 2020. The main aim of the therapy for Hodgkin lymphoma (HL), which hav...
Guardado en:
Autor principal: | Elena A. Demina |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/772208517a7b4f479036d2979c08965d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai C, et al.
Publicado: (2019) -
Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
por: Oncale MB, et al.
Publicado: (2017) -
Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas
por: Irina V. Poddubnaya, et al.
Publicado: (2021) -
Modern possibilities of therapy for primary cutaneous T-cell lymphomas: the first results of the use of brentuximab vedotin in the Russian Federation
por: Liliya G. Gorenkova, et al.
Publicado: (2021) -
New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
por: Irina V. Poddubnaya, et al.
Publicado: (2020)